| Literature DB >> 24038506 |
Kimihide Kusafuka1, Tetsuro Onitsuka, Koji Muramatsu, Tomoko Miki, Chika Murai, Toshihito Suda, Tomohito Fuke, Tomoyuki Kamijo, Yoshiyuki Iida, Takashi Nakajima.
Abstract
BACKGROUND: Salivary duct carcinoma with rhabdoid features is extremely rare.Entities:
Keywords: carcinoma ex pleomorphic adenoma; immunohistochemistry; rhabdoid cells; salivary duct carcinoma; ultrastructure
Mesh:
Year: 2013 PMID: 24038506 PMCID: PMC4296234 DOI: 10.1002/hed.23466
Source DB: PubMed Journal: Head Neck ISSN: 1043-3074 Impact factor: 3.147
Figure 1MR image revealed an irregular-shaped mass with low intensity in the left parotid gland (white arrows) with T2 resonance imaging (case 1).
Figure 2Histological findings of case 1. (A) The tumor showed a hyalinized nodule in the central area and an invasive component around it (whole mount hematoxylin-eosin stained section). (B) Part of the hyalinized nodule (B area in A: hematoxylin-eosin stain: original magnification ×200) showed spindle-shaped neoplastic myoepithelial cells in the myxoid stroma, which showed the typical histology of pleomorphic adenoma. (C) Atypical ductal carcinoma in situ component (C area in A: hematoxylin-eosin stain: original magnification ×200) was observed in the peripheral portion of pleomorphic adenoma. (D) Invasive component (D area in A: hematoxylin-eosin stain: original magnification ×200) showed the diffuse growth of noncoherent, ovoid-shaped, carcinoma cells. (D: inset: hematoxylin-eosin stain: original magnification ×400) Carcinoma cells showed eccentric nuclei, marked cellular atypia and 1 large nucleolus with eosinophilic cytoplasm. (E) Typical histology of salivary duct carcinoma, which consisted of irregular-shaped atypical glands with eosinophilic cytoplasm, relatively large cytoplasm and marked nuclear atypia, was seen at the invasive component (E area in A: hematoxylin-eosin stain: original magnification ×200).
Figure 3Pathological findings of case 2. (A) Macroscopically, the main tumor showed cystic change (asterisks) and included a yellowish nodule (black arrows). The tumor expanded from the right submandibular gland (white arrows). (B) Low magnification view of histology indicated a hyalinized nodule, which was a preexisting pleomorphic adenoma (arrows), and the invasive component around the nodule, which was accompanied with cystic change (asterisk; whole mount hematoxylin-eosin stain section). (C) Invasive component showed sheet-like growth of adenocarcinoma cells with central necrosis (hematoxylin-eosin stain: original magnification ×200). (D) Part of the metastatic lesions showed diffuse proliferation of rhabdoid cells, which were similar to those of case 1 (hematoxylin-eosin stain: original magnification ×200).
Antibodies used in this study and their results.
| Case 1 | Case 2 | |||||||
|---|---|---|---|---|---|---|---|---|
| Antigen | Clone | P/M | Source | PA | SDCRF | PA | SDCRF | AdC |
| pan-CK | AE-1/3 | M | Signet Laboratories (Denham, MA, USA) | (myo)+ | ++ | (myo)+ | ++ | ++ |
| EMA | E29 | M | Progen Biotechnik (Geiderberg, Germany) | − | ++ | − | ++ | ++ |
| CK7 | OV-TL-12/30 | M | DakoCytomation (Carpinteria, CA, USA) | − | ++ | − | ++ | ++ |
| LMWK | CAM5.2 | M | Becton Dickinson (San Jose, CA, USA) | (myo)f+ | ++ | − | ++ | ++ |
| CK14 | LL002 | M | Chemicon International (Temecula, CA, USA) | (myo)+ | − | (myo)f+ | − | − |
| CK5/6 | D5/16B4 | M | DakoCytomation (Carpinteria, CA, USA) | (myo)+ | − | (myo)f+ | − | − |
| p63 | 4A4 | M | LAB Vision (Fremont, CA, USA) | (myo)f+ | − | − | − | f+ |
| calponin | CALP | M | DakoCytomation (Carpinteria, CA, USA) | (myo)+ | − | (myo)f+ | N.D. | − |
| S-100 protein | P | DakoCytomation (Carpinteria, CA, USA) | (myo)+ | − | − | − | − | |
| vimentin | V9 | M | DakoCytomation (Carpinteria, CA, USA) | (myo)+ | − | (myo)+ | − | f+ |
| GCDFP-15 | NCL-GCDFP-15 | M | Novocastra Laboratories (Newcastle upon Tyne, UK) | − | ++ | − | ++ | − |
| AR | AR441 | M | DakoCytomation (Carpinteria, CA, USA) | − | ++ | − | ++ | − |
| ER | SP-1 | M | Thermo Scientific (Fremint, CA, USA) | − | − | − | − | − |
| PgR | 1A6 | M | Novocastra Laboratories (Newcastle upon Tyne, UK) | − | − | − | − | − |
| Her-2 | P | DakoCytomation (Carpinteria, CA, USA) | − | 2+ | − | − | − | |
| EGFR | NCL-L-EGFR | M | Novocastra Laboratories (Newcastle upon Tyne, UK) | f+ | − | − | − | f+ |
| PSA | P | DakoCytomation (Carpinteria, CA, USA) | − | + | − | − | − | |
| CEA | CEM10 | M | TeKaRa Bio (Shiga, Japan) | f+ | − | − | p+ | − |
| CA125 | OC125 | M | DakoCytomation (Carpinteria, CA, USA) | p+ | f+ | − | ++ | ++ |
| CA19-9 | 116NS199 | M | DakoCytomation (Carpinteria, CA, USA) | p+ | f+ | − | − | − |
| MUC1 | NCL-Mab695MUC1 | M | Novocastra Laboratories (Newcastle upon Tyne, UK) | (SDC)p+ | + | − | ++ | p+ |
| MUC2 | NCL-CLP58MUC2 | M | Novocastra Laboratories (Newcastle upon Tyne, UK) | − | − | − | f+ | − |
| MUC4 | 1G8 | M | Santa Cruz Biotechnology (Santa Cruz, CA, USA) | − | − | − | − | − |
| MUC5AC | CLH2MUC%AC | M | Novocastra Laboratories (Newcastle upon Tyne, UK) | (SDC)f+ | − | − | p+ | − |
| MUC5B | P | Santa Cruz Biotechnology (Santa Cruz, CA, USA) | − | − | − | − | − | |
| MUC6 | CLH5MUC6 | M | Novocastra Laboratories (Newcastle upon Tyne, UK) | (SDC)p+ | f+ | − | + | − |
| p16 | 484 | M | DakoCytomation (Carpinteria, CA, USA) | N.D. | N.D. | − | ++ | ++ |
| p53 | DO-7 | M | DakoCytomation (Carpinteria, CA, USA) | f+ | + | − | − | w+ |
| Ki-67 | MIB-1 | M | DakoCytomation (Carpinteria, CA, USA) | 5.1% | 43.2% | 0.4% | 94.2% | 93.2% |
Abbreviations: PA, pleomorphic adenoma; SDCRF, salivary duct carcinoma with rhabdoid feature; AdC, adenocarcinoma, not otherwise specified; CK, cytokeratin; LMWK, low-molecular-weight keratin; EMA, epithelial membrane antigen; GCDFP, gross cystic disease fluid protein; AR, androgen receptor; ER, estrogen receptor; PgR, progesterone receptor; EGFR, epidermal growth factor receptor; PSA, prostate-specific antigen; CEA, carcinoembryonic antigen; CA, carbohydrate antigen; -, negative; f+, focally positive; p+, partially positive; +, positive; ++, diffusely and strongly positive; (myo), myoepithelial cells.
Figure 4Immunohistochemical results for rhabdoid cells in both cases. Rhabdoid cells were positive for pan-cytokeratin (CK) (A: case 2: immunostaining: original magnification ×200), gross cystic disease fluid protein-15 (GCDFP-15). (B: case 1: immunostaining ×200) androgen receptor (AR) (C: case 2: immunostaining: original magnification ×200). They were positive for Her-2 (D: immunostaining: original magnification ×200) and p53 (E: immunostaining: original magnification ×200) in case 1. They were also diffusely positive for Ki-67 in case 2 (F: immunostaining: original magnification ×200).
Figure 5Immunohistochemical findings of in situ lesion in case 1. In the peripheral area of the residual pleomorphic adenoma, the inner atypical ductal cells were positive for androgen receptor (AR) (A: immunostaining: original magnification ×200) and the neoplastic myoepithelial cells around the atypical ductal cells (asterisks) were positive for cytokeratin (CK)14 (B: immunostaining: original magnification ×200).
Figure 6Ultrastructural finding of case 1. The condensation of the intermediated filaments and dilated segments of rough endoplasm reticulum were frequently observed in tumor cell cytoplasm. Scale bar = 1 μm.